Increased wound-response revealed by proteomics of estrogen receptor-negative breast cancers

被引：0
|
作者：
Neubauer, H. [1 ]
Clare, S. [2 ]
Sotlar, K. [3 ]
Wallwiener, D. [1 ]
Cahill, M. A. [4 ]
Solomayer, E. [1 ]
Fehm, T. [1 ]
机构：
[1] Univ Tubingen, Dept Obstet & Gynecol, D-7400 Tubingen, Germany
[2] Indiana Univ, Sch Med, Dept Surg, Div Breast Surg Oncol, Indianapolis, IN 46202 USA
[3] Univ Tubingen, Dept Pathol, Tubingen, Germany
[4] ProteoSys AG, Mainz, Germany
来源：
ONKOLOGIE | 2008年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：34 / 35
页数：2
相关论文
共 50 条
  • [1] Increased wound-response revealed by proteomics of estrogen receptor-negative breast cancers
    Neubauer, H.
    Sotlar, K.
    Wallwiener, D.
    Cahill, M. A.
    Solomayer, E.
    Fehm, T.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2008, 68 : S61 - S62
  • [2] NFIB is a potential target for estrogen receptor-negative breast cancers
    Moon, Hyeong-Gon
    Hwang, Ki-Tae
    Kim, Jeong-Ah
    Kim, Hee Sung
    Lee, Min-Joo
    Jung, Eun-Mi
    Ko, Eunyoung
    Han, Wonshik
    Noh, Dong-Young
    MOLECULAR ONCOLOGY, 2011, 5 (06) : 538 - 544
  • [3] Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers
    William B Archey
    Kristen A McEachern
    Mark Robson
    Kenneth Offit
    Susan AJ Vaziri
    Graham Casey
    Åke Borg
    Bradley A Arrick
    Oncogene, 2002, 21 : 7034 - 7041
  • [4] Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers
    Archey, WB
    McEachern, KA
    Robson, M
    Offit, K
    Vaziri, SAJ
    Casey, G
    Borg, Å
    Arrick, BA
    ONCOGENE, 2002, 21 (46) : 7034 - 7041
  • [5] Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers
    Hatem, Rana
    Labiod, Dalila
    Chateau-Joubert, Sophie
    de Plater, Ludmilla
    El Botty, Rania
    Vacher, Sophie
    Bonin, Florian
    Servely, Jean-Luc
    Dieras, Veronique
    Bieche, Ivan
    Marangoni, Elisabetta
    INTERNATIONAL JOURNAL OF CANCER, 2016, 138 (10) : 2510 - 2521
  • [6] GATA3 Is a Marker of Estrogen Receptor-Positive but Not Estrogen Receptor-Negative Breast Cancers
    Piscuoglio, S.
    Wen, Y. H.
    Martelotto, L. G.
    Rocco, E. Guerini
    Akram, M.
    Jungbluth, A. A.
    Brogi, E.
    Weigelt, B.
    Reis-Filho, J. S.
    MODERN PATHOLOGY, 2014, 27 : 76A - 76A
  • [7] GATA3 Is a Marker of Estrogen Receptor-Positive but Not Estrogen Receptor-Negative Breast Cancers
    Piscuoglio, S.
    Wen, Y. H.
    Martelotto, L. G.
    Rocco, E. Guerini
    Akram, M.
    Jungbluth, A. A.
    Brogi, E.
    Weigelt, B.
    Reis-Filho, J. S.
    LABORATORY INVESTIGATION, 2014, 94 : 76A - 76A
  • [8] Sex Hormone Levels and Risks of Estrogen Receptor-Negative and Estrogen Receptor-Positive Breast Cancers
    Farhat, Ghada N.
    Cummings, Steven R.
    Chlebowski, Rowan T.
    Parimi, Neeta
    Cauley, Jane A.
    Rohan, Thomas E.
    Huang, Alison J.
    Vitolins, Mara
    Hubbell, F. Allan
    Manson, JoAnn E.
    Cochrane, Barbara B.
    Lane, Dorothy S.
    Lee, Jennifer S.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (07): : 562 - 570
  • [9] Genes Dysregulated to Different Extent or Oppositely in Estrogen Receptor-Positive and Estrogen Receptor-Negative Breast Cancers
    Zhou, Xianxiao
    Shi, Tongwei
    Li, Bailiang
    Zhang, Yuannv
    Shen, Xiaopei
    Li, Hongdong
    Hong, Guini
    Liu, Chunyang
    Guo, Zheng
    PLOS ONE, 2013, 8 (07):
  • [10] Characterizing Clinicopathologic Features of Estrogen Receptor-Positive/Progesterone Receptor-Negative Breast Cancers
    Fei, Fei
    Siegal, Gene P.
    Wei, Shi
    CLINICAL BREAST CANCER, 2022, 22 (07) : E788 - E797
12345